Orion Porfolio Solutions LLC Sells 1,158 Shares of Medpace Holdings, Inc. $MEDP

Orion Porfolio Solutions LLC cut its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 24.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,559 shares of the company’s stock after selling 1,158 shares during the period. Orion Porfolio Solutions LLC’s holdings in Medpace were worth $1,830,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of MEDP. NewEdge Advisors LLC raised its holdings in shares of Medpace by 22.1% in the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after purchasing an additional 190 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Medpace by 3.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after purchasing an additional 3,010 shares during the last quarter. Geneos Wealth Management Inc. boosted its holdings in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in Medpace in the 2nd quarter worth about $296,000. Finally, Aviva PLC grew its position in Medpace by 58.5% in the 2nd quarter. Aviva PLC now owns 2,883 shares of the company’s stock worth $905,000 after purchasing an additional 1,064 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and dropped their target price for the stock from $462.00 to $419.00 in a research report on Wednesday, February 18th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Robert W. Baird raised Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price objective on the stock in a research report on Tuesday, February 10th. Finally, Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective for the company in a research note on Friday, February 13th. Five equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $486.67.

Medpace Stock Up 2.3%

MEDP opened at $477.72 on Thursday. The stock has a market cap of $13.56 billion, a price-to-earnings ratio of 31.22, a PEG ratio of 2.24 and a beta of 1.44. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $628.92. The company’s 50-day moving average price is $528.39 and its two-hundred day moving average price is $539.24.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.49. The company had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. Medpace’s quarterly revenue was up 32.0% compared to the same quarter last year. During the same quarter last year, the business posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.